AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36427162
Drug: Caplacizumab 10
RxNorm normalized name: caplacizumab
DrugBank: Caplacizumab (DB06081)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Caplacizumab 10 mg administered daily during plasma exchange and for 30 days afterward, in combination with immunosuppressive treatment
Trial: 36427183
Drug: Palbociclib in
RxNorm normalized name: Product containing palbociclib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib in combination with endocrine therapy (aromatase inhibitor or fulvestrant) as first-line treatment
Trial: 36427183
Drug: Palbociclib in
RxNorm normalized name: Product containing palbociclib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib in combination with endocrine therapy
Trial: 36427183
Drug: Second-line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatment effectiveness
Trial: 36427229
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for NSTI (including surgery and broad-spectrum antibiotics)
Trial: 36427234
Drug: Adapted Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted Physical Activity (APA) along with chemotherapy, supervised by a qualified kinesiologist, including endurance and resistance training at moderate intensity 3 times a week for 6 months.
Trial: 36427234
Drug: Adapted Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted Physical Activity (APA) along with chemotherapy.
Trial: 36427234
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (control group).
Trial: 36427645
Drug: Moderately hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes, delivering 6750 cGy to the prostate and 4500 cGy to the pelvic lymph nodes in 25 daily fractions.
Trial: 36427645
Drug: Moderately hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes.
Trial: 37226504
Drug: SCB-2019 vaccine
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB-2019 vaccine
Trial: 36433829
Drug: isatuximab 20
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: isatuximab 20 mg/kg QW/Q2W
Trial: 36434392
Drug: Combination hypofractionated
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination hypofractionated stereotactic body radiation therapy with single-dose durvalumab (anti-PD-L1)
Trial: 36434554
Drug: Talazoparib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (1 mg/day) and Avelumab (800 mg on days 1 and 15)
Trial: 36435266
Drug: BAY2586116 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY2586116 (160 μg) nasal spray
Trial: 36435266
Drug: BAY2586116 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY2586116 (3 μg) nasal drops
Trial: 36435266
Drug: BAY2586116 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY2586116 (30 μg) nasal drops
Trial: 36435928
Drug: Neural crest
RxNorm normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neural crest tumour treatment
Trial: 36435949
Drug: New formula
RxNorm normalized name: Correct (New Formula)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formula for calculating Lp(a)-C from molar measurement of Lp(a) (Lp(a) nmol/L × 0.077 = Lp(a)-C mg/dL)
Trial: 36436013
Drug: Maternal serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP)
Trial: 36436128
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of endocrine therapy (ET)
Trial: 36436128
Drug: Non-persistence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-persistence of endocrine therapy (ET)
Trial: 36436128
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and symptom burden
Trial: 36436320
Drug: Fampridine treatment
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fampridine treatment for 14 days
Trial: 36436423
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine therapy (NET) with genomic testing using 70-gene and 80-gene signatures
Trial: 36436615
Drug: Mean heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean heart dose ≥10 Gy
Trial: 36436615
Drug: Mean heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean heart dose <10 Gy
Trial: 36436704
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of CoronaVac (N = 134)
Trial: 36436704
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of BNT162b2 (N = 133)
Trial: 36436704
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of ChAdOx1 (N = 127)
Trial: 36437418
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccine (BBIBP-CorV), 2 doses on days 0 and 21
Trial: 36438589
Drug: Suprachoroidal injection
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprachoroidal injection of triamcinolone acetonide (TA) 4 mg/0.1 mL
Trial: 36438753
Drug: Fermented PV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented PV (70 mL daily for 8 weeks)
Trial: 36438753
Drug: Placebo (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (70 mL daily for 8 weeks)
Trial: 36440533
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (none, one or two doses)
Trial: 36440533
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (fully vaccinated)
Trial: 36441357
Drug: PF-06462700 (equine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06462700 (equine anti-thymocyte immunoglobulin) administered intravenously at 40 mg/kg/day for 4 days
Trial: 36441736
Drug: Oral olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral olanzapine (OLA)
Trial: 36441736
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (PL)
Trial: 36442665
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behavioral therapy
Trial: 36442892
Drug: Intravenous OP-724
RxNorm normalized name: OP-1
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous OP-724 infusion at a dosage of 280 mg/m²
Trial: 36442892
Drug: Intravenous OP-724
RxNorm normalized name: OP-1
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous OP-724 infusion at a dosage of 380 mg/m²
Trial: 36443171
Drug: CUD-002 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUD-002 vaccine consisting of dendritic cells loaded with mRNA encoding personalized tumor neoantigens
Trial: 36444224
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention initiated during chemotherapy (group A)
Trial: 36444224
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention initiated after chemotherapy (group B)
Trial: 36444374
Drug: BGF (budesonide/glycopyrronium/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF (budesonide/glycopyrronium/formoterol fumarate dihydrate) 320/14.4/10 µg
Trial: 36444834
Drug: Unmarried patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmarried patients receiving reperfusion treatment
Trial: 36445410
Drug: Intratumoral V937
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral V937 + intravenous pembrolizumab 2 mg/kg Q3W
Trial: 36445467
Drug: Buccal wall
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal wall thickness
Trial: 36445882
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) and iron supplements as per guidelines
Trial: 36445944
Drug: Fenofibrate (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (oral PPAR-α agonist)
Trial: 36446452
Drug: Neo-adjuvant therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant therapy, surgery and adjuvant chemotherapy
Trial: 36446452
Drug: Post-treatment complications
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment complications
Trial: 36448227
Drug: Nelarabine continuous
RxNorm normalized name: Nelarabine
DrugBank: Nelarabine (DB01280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelarabine continuous infusion (CI) for 5 days (120 hours) at escalating doses from 100 to 800 mg/m2
Trial: 36448274
Drug: 10% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% human intravenous immunoglobulin (IVIg) BT595, total dose of 2 g/kg body weight over 2 or 5 days
Trial: 36450289
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for adherence and depression (CBT-AD) delivered by a nurse, conducted once weekly for 12 sessions.
Trial: 36450386
Drug: Selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective internal radiation therapy (SIRT) followed by nivolumab (240 mg every 2 weeks for up to 24 doses)
Trial: 36450938
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) at a dose of 5 mg/kg 24 hours prior to surgery
Trial: 36451114
Drug: Intensive inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive inpatient treatment program (APT + VITA)
Trial: 36451175
Drug: Decentralized PWUD-HCV
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decentralized PWUD-HCV care model using pangenotypic direct acting antivirals (DAAs) for HCV treatment.
Trial: 36451242
Drug: Fimasartan 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg (FMS/ALD + RSV)
Trial: 36451242
Drug: Fimasartan 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 60 mg/amlodipine 10 mg (FMS/ALD)
Trial: 36451242
Drug: Fimasartan 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 60 mg + rosuvastatin 20 mg (FMS + RSV)
Trial: 36451252
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (IVR) injections (0.5 mg/0.05 mL)
Trial: 36451252
Drug: Intravitreal conbercept
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal conbercept (IVC) injections (0.5 mg/0.05 mL)
Trial: 36451848
Drug: Dupilumab, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab, a monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13.
Trial: 36452171
Drug: BL10 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL10 gel
Trial: 36452171
Drug: EMLA gel
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA gel
Trial: 36452901
Drug: AGT103-T autologous
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGT103-T autologous T cell therapy
Trial: 36452951
Drug: Psychotropic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medications usage.
Trial: 36453122
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injection (pain group)
Trial: 36453122
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection (control group)
Trial: 36453667
Drug: Pilates intervention,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates intervention, details on dosage and duration not available
Trial: 36454054
Drug: Immunomodulatory and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory and/or immunosuppressive (IM/IS) drugs
Trial: 36454054
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with IM/IS drugs (Control)
Trial: 36455228
Drug: Trotabresib 30
RxNorm normalized name: Trotabresib
DrugBank: Trotabresib (DB17421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trotabresib 30 mg/day on days 1-4 before surgery, followed by maintenance trotabresib 45 mg/day 4 days on/24 days off after surgery
Trial: 36455412
Drug: Cobimetinib 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobimetinib 60 mg once daily for 21 days followed by a 7-day break and concurrent intravenous atezolizumab 840 mg every 2 weeks (Cohort A)
Trial: 36456200
Drug: N-acetyl-l-leucine (NALL)
RxNorm normalized name: N-acetyl-l-leucine
DrugBank: L-Acetylleucine (DB16956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-l-leucine (NALL) administered orally at 4 g/d for patients ≥13 years, weight-tiered doses for patients 6-12 years for 6 weeks.
Trial: 36456200
Drug: N-acetyl-l-leucine (NALL)
RxNorm normalized name: N-acetyl-l-leucine
DrugBank: L-Acetylleucine (DB16956)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-l-leucine (NALL)
Trial: 36456573
Drug: Ganetespib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib (150 mg/m) in combination with standard chemotherapy
Trial: 36456573
Drug: Standard neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neoadjuvant chemotherapy (NAC)
Trial: 36457860
Drug: EPP-AF® (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPP-AF® (200 mg/day for 4 weeks)
Trial: 36458825
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg)
Trial: 36459100
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise training; details on dosage and duration not available.
Trial: 36459284
Drug: Pamiparib 60
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib 60 mg orally twice daily in 28-day continuous cycles
Trial: 36459673
Drug: Axatilimab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axatilimab (3 mg/kg given once every 4 weeks)
Trial: 36459994
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of rhu-GM-CSF
Trial: 36460537
Drug: Two-dose HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose HPV vaccination program
Trial: 36460537
Drug: One-dose HPV
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose HPV vaccination program
Trial: 36460794
Drug: Opaganib 500
RxNorm normalized name: Opaganib
DrugBank: Opaganib (DB12764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opaganib 500 mg BID
Trial: 36460794
Drug: Opaganib (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opaganib (up to 750 mg BID)
Trial: 36461087
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (cMDA) program
Trial: 36461750
Drug: Renin-angiotensin-aldosterone system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin-aldosterone system inhibitors or beta-blockers
Trial: 36461912
Drug: Rice Bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice Bran (RB) supplementation (15 g/day)
Trial: 36463104
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg and gemcitabine 1,250 mg/m²
Trial: 36463173
Drug: Family Treatment
RxNorm normalized name: AQP family protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Treatment Drug Court (FTDC)
Trial: 39697397
Drug: Medications for
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications for Opioid Use Disorder (MOUD)
Trial: 36463180
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation solution (TIS) once daily (OD) for 1 year
Trial: 36463214
Drug: Telemedicine-based program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine-based program (PARTNER UP) providing access to oral pre-exposure prophylaxis (PrEP) and medication for opioid use disorder (MOUD) through syringe services programs (SSPs). Initial in-person visit followed by weekly telemedicine visits in month 1 and monthly visits until month 6.
Trial: 36463561
Drug: Ixazomib-based triple-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib-based triple-drug therapy
Trial: 36465905
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Radium-223
Trial: 36466215
Drug: Emotional Awareness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotional Awareness and Expression Therapy (EAET) class
Trial: 36467452
Drug: Bosutinib 100
RxNorm normalized name: bosutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 100 mg QD to 400 mg QD
Trial: 36467452
Drug: Bosutinib treatment
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib treatment
Trial: 36467815
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitor de-escalation or discontinuation
Trial: 36468635
Drug: BMAC intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMAC intra-articular injection combined with subchondral BMAC injection
Trial: 36468635
Drug: BMAC intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMAC intra-articular injection alone
Trial: 36469095
Drug: Post-transplant CD45RA-depleted
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplant CD45RA-depleted donor lymphocyte infusions (DLI)
Trial: 36469103
Drug: Standard clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clinical measures (e.g., Nine-Hole Peg Test [9HPT]).
Trial: 36469250
Drug: Kollidon VA64®-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kollidon VA64®-based eliapixant formulation (400 mg; fasted)
Trial: 36469250
Drug: Immediate-release eliapixant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release eliapixant
Trial: 36469250
Drug: Two amorphous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two amorphous solid dispersion (ASD) formulations
Trial: 36469250
Drug: Suspension-based formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension-based formulation
Trial: 36469321
Drug: Pacritinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacritinib (400 mg on day 1 followed by 200 mg twice daily on days 2-14)
Trial: 36469840
Drug: Adavosertib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib monotherapy in patients with epithelial ovarian cancer
Trial: 36470149
Drug: Inhaled corticosteroid-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid-containing therapy
Trial: 36470745
Drug: Non-opioid analgesics
RxNorm normalized name: Non-opioid analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid analgesics (NSAID, paracetamol, metamizole)
Trial: 36470745
Drug: Non-opioid analgesics
RxNorm normalized name: Non-opioid analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid analgesics